Khoury, Katia; Meisel, Jane L.; Yau, Christina; Rugo, Hope S.; Nanda, Rita; Davidian, Marie; Tsiatis, Butch; Chien, A. Jo; Wallace, Anne M.; Arora, Mili; Rozenblit, Mariya; Hershman, Dawn L.; Zimmer, Alexandra; Clark, Amy S.; Beckwith, Heather; Elias, Anthony D.; Stringer-Reasor, Erica; Boughey, Judy C.; Nangia, Chaitali; Vaklavas, Christos; Omene, Coral; Albain, Kathy S.; Kalinsky, Kevin M.; Isaacs, Claudine; Tseng, Jennifer; Torres, Evanthia T. Roussos; Thomas, Brittani; Thomas, Alexandra; Sanford, Amy; Balassanian, Ronald; Ewing, Cheryl; Yeung, Kay; Sauder, Candice; Sanft, Tara; Pusztai, Lajos; Trivedi, Meghna S.; Outhaythip, Ashton; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Beedle, Carolyn; Perlmutter, Jane; Pohlmann, Paula; Shatsky, Rebecca A.; Demichele, Angela; Yee, Douglas; van't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.

Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Datopotamab-deruxtecan联合durvalumab治疗早期乳腺癌: 序贯多重分配随机I-SPY2.2 2期试验

NATURE MEDICINE

IF50

2024-09-144

PRE

Shatsky, Rebecca A.; Trivedi, Meghna S.; Yau, Christina; Nanda, Rita; Rugo, Hope S.; Davidian, Marie; Tsiatis, Butch; Wallace, Anne M.; Chien, A. Jo; Stringer-Reasor, Erica; Boughey, Judy C.; Omene, Coral; Rozenblit, Mariya; Kalinsky, Kevin; Elias, Anthony D.; Vaklavas, Christos; Beckwith, Heather; Williams, Nicole; Arora, Mili; Nangia, Chaitali; Torres, Evanthia T. Roussos; Thomas, Brittani; Albain, Kathy S.; Clark, Amy S.; Falkson, Carla; Hershman, Dawn L.; Isaacs, Claudine; Thomas, Alexandra; Tseng, Jennifer; Sanford, Amy; Yeung, Kay; Boles, Sarah; Chen, Yunni Yi; Huppert, Laura; Jahan, Nusrat; Parker, Catherine; Giridhar, Karthik; Howard, Frederick M.; Blackwood, M. Michele; Sanft, Tara; Li, Wen; Onishi, Natsuko; Asare, Adam L.; Beineke, Philip; Norwood, Peter; Brown-Swigart, Lamorna; Hirst, Gillian L.; Matthews, Jeffrey B.; Moore, Brian; Symmans, W. Fraser; Price, Elissa; Heditsian, Diane; Lestage, Barbara; Perlmutter, Jane; Pohlmann, Paula; Demichele, Angela; Yee, Douglas; van 't Veer, Laura J.; Hylton, Nola M.; Esserman, Laura J.

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

在ER阳性，HER2-negative晚期乳腺癌女性中，下一代口服SERD camizestrant的I期剂量递增和扩展试验: SERENA-1单药治疗结果

ANNALS OF ONCOLOGY

IF65.4

2024-08-016

OAAI

SERENA-1: Results from a Phase 1 study (Parts I/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer

SERENA-1: 1期研究 (I/J部分) 的结果，该研究测试了ER，HER2晚期乳腺癌女性的下一代口服选择性雌激素受体降解剂 (SERD) camizestrant (AZD9833) 与capivasertib的组合

CANCER RESEARCH

IF16.6

2024-05-021

PRE

Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2023-08-313

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-08-2111

OAAI

The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

CANCER RESEARCH

IF16.6

2023-03-012

Morrow, Christopher; Carnevalli, Larissa; Baird, Richard D.; Brier, Tim; Ciardullo, Carmela; Cureton, Natalie; Lawson, Mandy; McEwen, Robert; Nikolaou, Myria; Armstrong, Anne; Bermejo, Begona; Calvo, Emiliano; Ciruelos, Eva; Garcia-Corbacho, Javier; Hamilton, Erika; Incorvati, Jason; Kabos, Peter; Oliveira, Mafalda; Patel, Manish R.; Ruiz-Borrego, Manuel; Turner, Nicholas; Twelves, Chris; Vaklavas, Christos; Carroll, Danielle; Ching, Steven; Cvetesic, Nevena; DuPont, Michelle; Gibbons, Lisa; Mathewson, Alastair; Maudsley, Rhiannon; Gutierrez, Pablo Morentin; Reddy, Avinash; Rodriguez-Canales, Jaime; Ros, Susana; Sudhan, Dhivya; Sykes, Andy; Whitson, David; Klinowska, Teresa; Lindemann, Justin

Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

CANCER RESEARCH

IF16.6

2023-03-015

PRE

Isaacs, Claudine; Nanda, Rita; Chien, Jo; Trivedi, Meghna S.; Stringer-Reasor, Erica; Vaklavas, Christos; Boughey, Judy C.; Sanford, Amy; Wallace, Anne; Clark, Amy S.; Thomas, Alexandra; Albain, Kathy S.; Kennedy, Laura C.; Sanft, Tara B.; Kalinsky, Kevin; Han, Hyo S.; Williams, Nicole; Arora, Mili; Elias, Anthony; Falkson, Carla; Asare, Smita; Lu, Ruixiao; Pitsouni, Maria; Wilson, Amy; Perlmutter, Jane; Rugo, Hope; Schwab, Richard; Symmans, W. Fraser; Hylton, Nola M.; Van't Veer, Laura; Yee, Douglas; DeMichele, Angela; Berry, Donald; Esserman, Laura J.

SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer

CANCER RESEARCH

IF16.6

2023-03-017

Turner, Nicholas; Vaklavas, Christos; Calvo, Emiliano; Garcia-Corbacho, Javier; Incorvati, Jason; Borrego, Manuel Ruiz; Twelves, Chris; Armstrong, Anne; Bermejo, Begona; Hamilton, Erika; Oliveira, Mafalda; Ciruelos, Eva; Kabos, Peter; Patel, Manish R.; Borrell, Maria; Burris, Howard; de Paula, Bruno; Falcon, Alejandro; Hernando, Cristina; Moreno, Irene; O'Brien, Ciara S.; Shagisultanova, Elena; Ruiz, Ivan Victoria; Wang, Judy S.; Wei, Mei; Brier, Tim; Carroll, Danielle; Ciardullo, Carmela; Gibbons, Lisa; Irurzun-Arana, Itziar; Jack, Tony; Kirova, Bistra; Klinowska, Teresa; Lindemann, Justin; Maidment, Julie; Mathewson, Alastair; Maudsley, Rhiannon; McEwen, Robert; Morrow, Christopher; Sykes, Andy; Baird, Richard D.

PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

CANCER RESEARCH

IF16.6

2023-03-011

PRE

Stringer-Reasor, Erica; Shatsky, Rebecca A.; Chien, Jo; Wallace, Anne; Boughey, Judy C.; Albain, Kathy S.; Han, Hyo S.; Nanda, Rita; Isaacs, Claudine; Kalinsky, Kevin; Mitri, Zahi; Clark, Amy S.; Vaklavas, Christos; Thomas, Alexandra; Trivedi, Meghna S.; Lu, Janice; Asare, Smita; Lu, Ruixiao; Pitsouni, Maria; Wilson, Amy; Perlmutter, Jane; Rugo, Hope; Schwab, Richard; Symmans, W. Fraser; Hylton, Nola M.; Van 't Veer, Laura; Yee, Douglas; DeMichele, Angela; Berry, Donald; Esserman, Laura J.

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

BREAST CANCER RESEARCH AND TREATMENT

IF3

2023-02-031

OAAI

Automated lesion detection of breast cancer in [18F] FDG PET/CT using a novel AI-Based workflow

使用基于AI的新型工作流在 [18F] FDG PET/CT中自动检测乳腺癌的病变

FRONTIERS IN ONCOLOGY

IF3.3

2022-11-153

OAAI

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

用于药物发现和精确肿瘤学的人类乳腺癌衍生异种移植物和类器官平台

NATURE CANCER

IF28.5

2022-02-24184

OAAI

Guillen, Katrin P.; Fujita, Maihi; Butterfield, Andrew J.; Scherer, Sandra D.; Bailey, Matthew H.; Chu, Zhengtao; DeRose, Yoko S.; Zhao, Ling; Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Toner, Jennifer; Wang, Guoying; Qiao, Yi; Huang, Xiaomeng; Greenland, Jeffery A.; Vahrenkamp, Jeffery M.; Lum, David H.; Factor, Rachel E.; Nelson, Edward W.; Matsen, Cindy B.; Poretta, Jane M.; Rosenthal, Regina; Beck, Anna C.; Buys, Saundra S.; Vaklavas, Christos; Ward, John H.; Jensen, Randy L.; Jones, Kevin B.; Li, Zheqi; Oesterreich, Steffi; Dobrolecki, Lacey E.; Pathi, Satya S.; Woo, Xing Yi; Berrett, Kristofer C.; Wadsworth, Mark E.; Chuang, Jeffrey H.; Lewis, Michael T.; Marth, Gabor T.; Gertz, Jason; Varley, Katherine E.; Welm, Bryan E.; Welm, Alana L.

A phase I/Ib trial of the CDK4/6 antagonist ribociclib (RIB) and the HDAC inhibitor belinostat (BEL) in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE)

CANCER RESEARCH

IF16.6

2022-02-150

PRE

Christos Vaklavas

个人简介

教育背景

工作经历

荣誉奖项

研究方向